MK-2206 in Recurrent Nasopharyngeal Carcinoma
To evaluate the activity and safety of MK-2206 in patients with recurrent or metastatic nasopharyngeal carcinoma (NPC)
Recurrent Nasopharyngeal Carcinoma
DRUG: MK-2206
The proportion of patients alive and progression-free at 6 months along with the confirmed response rate as a dual primary endpoint, 3 years
Adverse events, 2 Years|Overall survival, 3 years|Progression-free survival, 3 Years|RECIST-based subjective response, 3 Years|Laboratory correlates: pharmacokinetics, plasma EBV DNA half-life, 3 years|treatment tolerability, 2 years|duration of response, 3 years
To evaluate the activity and safety of MK-2206 in patients with recurrent or metastatic nasopharyngeal carcinoma (NPC)